One of the most discussed — and most misunderstood — areas of integrative neurology. Here's what the science actually says.
What Are Cannabinoids?
Cannabinoids are compounds that interact with the body's endocannabinoid system (ECS) — a regulatory network of receptors, enzymes, and endogenous ligands found throughout the brain, immune system, and peripheral nervous system.
- CB1 receptors — concentrated in the brain and CNS; involved in pain, mood, memory, and motor control
- CB2 receptors — concentrated in immune cells; involved in inflammation regulation
Key Cannabinoids in Research
CBD (Cannabidiol)
- Non-psychoactive; does not produce a "high"
- Interacts with CB1 and CB2 receptors indirectly, and with multiple other receptor systems
- FDA-approved as Epidiolex for certain epilepsy syndromes
THC (Tetrahydrocannabinol)
- Psychoactive; direct CB1 agonist
- Approved in combination with CBD as Sativex (nabiximols) in multiple countries for MS spasticity
CBG, CBN, CBC
- Minor cannabinoids with emerging research profiles
- CBG shows early anti-inflammatory and neuroprotective properties in preclinical studies
What the Research Shows in Neurological Conditions
MS Spasticity — Strongest Evidence
Sativex (THC:CBD oromucosal spray) is approved in over 25 countries for MS-related spasticity. Clinical trials show significant reduction in patient-reported spasticity scores, improved sleep quality, and reduction in spasm frequency.
Pain Management
- Multiple trials show cannabinoids reduce central neuropathic pain in MS
- CBD alone shows more modest effects than THC:CBD combinations for pain
Neuroinflammation — Preclinical Promise
Animal studies consistently show CBD reduces microglial activation, decreases pro-inflammatory cytokines (TNF-alpha, IL-6), protects against blood-brain barrier disruption, and shows neuroprotective effects in EAE (MS animal model).
Important caveat: Preclinical results do not always translate to human outcomes. Human trials specifically examining CBD's effect on MS disease activity are limited and ongoing.
Sleep & Anxiety
- CBD shows consistent anxiolytic effects in human trials
- Improves sleep quality, particularly sleep onset
What the Research Does NOT Show
- CBD has not been proven to slow MS progression or prevent relapses in humans
- CBD is not a replacement for disease-modifying therapies
- Optimal dose, formulation, and delivery method remain unclear
Safety & Drug Interactions
- Drug interactions — CBD inhibits CYP450 liver enzymes, affecting metabolism of many medications including some DMTs and blood thinners
- Liver enzymes — high-dose CBD associated with elevated liver enzymes in some trials
- Quality control — third-party tested products with Certificates of Analysis (COA) are essential
- Pregnancy and breastfeeding — not recommended
Always disclose CBD use to your neurologist — particularly if on DMTs or other medications.
Choosing a Quality CBD Product
- Full-spectrum or broad-spectrum — contains multiple cannabinoids and terpenes
- Third-party tested — independent lab COA verifying cannabinoid content and absence of contaminants
- US-grown hemp — subject to agricultural regulations
- Clear dosing information — mg of CBD per serving, not just per bottle
This article is for educational purposes only and does not constitute medical advice. CBD products are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you are taking prescription medications.
0 comments